ArticleAMB Express2026
In vitro nano‑emodin-associated exosome‑mediated aPDT against Acinetobacter baumannii.
Article in AMB Express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Biofilm-forming Acinetobacter baumannii, particularly multidrug-resistant (MDR) strains, present major challenges in burn wound treatment. This study evaluated the antibacterial and antibiofilm efficacy of exosomes associated with nano-emodin (NE-Exos) combined with antimicrobial photodynamic therapy (aPDT) against A. baumannii. Antibacterial and antibiofilm activities were evaluated against the standard strain (ATCC 19606) and clinical isolates of A. baumannii, including MDR, extensively drug-resistant (XDR), and non-MDR/non-XDR strains. Minimum inhibitory and bactericidal concentrations (MIC, MBC), biofilm-inhibitory and eradication concentrations (MBIC, MBEC), drug release, hemolysis, and expression of biofilm-associated genes (abaI, bap) were evaluated. Nano-emodin and NE-Exos showed inhibitory and antibacterial activities with MIC and MBC values ranging from 15 to 39 μg/mL and 30 to 156 μg/mL, respectively. NE-Exos showed better antibiofilm efficacy compared to nano-emodin alone, especially in MDR isolates. The release of nano-emodin from NE-Exos reached 30.73% nano-emodin release at pH 5.5 after 300 min, compared to 27.56% and 23.76% at pH 7.4 and 8.5, respectively, and was associated with minimal hemolysis (0.015%). Furthermore, NE‑Exos combined with aPDT significantly downregulated the biofilm‑associated genes abaI and bap, with reductions of up to 10.96‑fold and 5.33‑fold, respectively (p < 0.001). Exosomes may have contributed to the observed antimicrobial effects, although their role appears to be as a carrier for nano‑emodin. These findings support NE‑Exos combined with aPDT as a promising in vitro strategy against A. baumannii biofilms; however, the lack of direct quantification of nano‑emodin encapsulation should be considered a study limitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.